Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer (Q36613969)

15 August 2017

1 reference

title

Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer (English)

1 reference

15 August 2017

Igor Astsaturov

1

1 reference

PubMed ID

17020453

15 August 2017

Roger B Cohen

series ordinal

2

1 reference

PubMed ID

17020453

15 August 2017

Paul Harari

series ordinal

3

1 reference

15 August 2017

1 September 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

9

1 reference

15 August 2017

1179-1193

1 reference

15 August 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Repopulation in radiation oncology: perspectives of clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Targeting signal transduction pathways in colorectal cancer--more than skin deep

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Molecularly-targeted therapies for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Radiation combined with EGFR signal inhibitors: head and neck cancer focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Clathrin-independent endocytosis of ubiquitinated cargos

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Bexarotene and erlotinib for aerodigestive tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epidermal growth factor receptor and its inhibition in radiotherapy:in vivofindings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Mutations in the EGFR: the importance of genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

A review of erlotinib and its clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1179

10.1586/14737140.6.9.1179

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17020453